Full Press Release Details
MiMedx Urges Shareholders to Vote Today FOR All of the Board s Highly Qualified
Nominees on the BLUE Proxy Card
The MiMedx Annual Meeting is This Coming Monday, June 17, 2019
MARIETTA, Ga., June 14, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader in advanced
wound care and an emerging therapeutic biologics company, encourages shareholders to vote FOR all of the Board s highly qualified nominees online or by telephone by following the easy instructions on the BLUE Proxy
Card. The 2018 Annual Meeting of Shareholders (the Annual Meeting ) will be held on Monday, June 17, 2019 shareholders are urged to vote the BLUE proxy card TODAY.
Vote FOR Board Refreshment and FOR MiMedx s New, Experienced and Objective Nominees.
The MiMedx Board of Directors has developed a comprehensive plan to refresh the composition of the Board in the near term while providing important business
oversight and leadership continuity. None of the incumbent directors whose terms expire at the Annual Meeting or the 2019 annual meeting of shareholders will stand for reelection. In their stead, the Board will nominate or appoint six new directors,
including our new CEO. Two of the candidates standing for election at the upcoming Annual Meeting were identified by one of the Company s largest shareholders, Prescience Point Capital Management LLC.
MiMedx s plan to refresh the composition of the Board with directors that will provide important business oversight and leadership can be implemented
ONLY if you vote on the BLUE proxy card FOR all of MiMedx s nominees.
In the Company s View, Mr. Petit Cannot
Be Allowed to Return to MiMedx In Any Capacity.
The Board unanimously opposes the return of Parker H. Pete Petit to
the Company in any capacity. In its independent investigation conducted with the assistance of King & Spalding LLP, a nationally recognized law firm, and KPMG LLP, which performed forensic accounting work, the Audit Committee of the Board
found that the evidence demonstrated that Mr. Petit and certain members of his management team engaged in material misconduct, which harmed MiMedx and its shareholders. The MiMedx Board unanimously recommends that shareholders do NOT
sign the white proxy card sent to you by, or on behalf of, Mr. Petit or his nominees.
All Three Leading Proxy Advisory Firms Recommend
Shareholders Vote the BLUE Proxy Card.
Institutional Shareholder Services ( ISS ), Glass, Lewis & Co. ( Glass Lewis ) and
Egan-Jones Proxy Services all recommended MiMedx shareholders vote FOR the Company s three director nominees on the BLUE proxy card and have indicated that they believe that Mr. Petit s return to MiMedx would be damaging
In its report dated June 10, 2019, ISS noted the following1:
In its report dated June 11, 2019, Glass Lewis
Both ISS and Glass Lewis recommended that shareholders vote
AGAINST the two shareholder proposals submitted by Mr. Petit.
Shareholders can vote by following the easy instructions on
the BLUE proxy card. With the annual meeting only days away, MiMedx shareholders are encouraged to vote now online or by telephone to ensure their shares are represented at the Annual Meeting.
Shareholders who have already voted using a white proxy card have the right to change their vote and can do so by following the easy instructions on the BLUE proxy card. Only the last dated vote will count.
The Company reminds shareholders that all materials regarding the Board s recommendations for the Annual Meeting are available at
Your Vote Is Important, No Matter How Many Or How Few Shares You Own.
If you have questions about how to vote your shares, or need additional assistance, please contact
the firm assisting MiMedx in the solicitation of proxies:
INNISFREE M&A INCORPORATED
Shareholders may call toll-free at 1 (877) 800-5195
Banks and Brokers may call 1 (212) 750-5833
Sidley Austin LLP is acting as legal advisor to MiMedx.
MiMedx is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for
multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by
employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.5 million allografts to date. For additional information, please visit www.mimedx.com.
This communication includes forward-looking
statements, including statements regarding the plan of MiMedx Group, Inc. (the Company ) to refresh the Board. Forward-looking statements may be identified by words such as believe, expect,
may, plan, potential, will, would and similar expressions and are based on current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the
Company cautions investors against placing undue reliance on such
statements. Actual results may differ materially from those set forth in the forward-looking statements as a result of various factors, including the results of any election at the Company s
2018 annual meeting of shareholders (the 2018 Annual Meeting ) or the Company s 2019 annual meeting of shareholders (the 2019 Annual Meeting ). There is no assurance that the Board s nominees will be elected at the
2018 Annual Meeting or the 2019 Annual Meeting. Any forward-looking statements speak only as of the date of this communication, and except as required by law, the Company assumes no obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Corporate & Investor Communications
Joele Frank, Wilkinson Brimmer Katcher
Andy Brimmer / Jed Repko
/ Annabelle Rinehart